Munder, M.

Suppression of T-cell functions by human granulocyte arginase

Munder, M. (2006) · Blood

Immune cells in cancerAmino Acid Enzymes and Metabolism

Cited by 417

Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity

Munder, M. (2005) · Blood

Neutrophil, Myeloperoxidase and Oxidative MechanismsAmino Acid Enzymes and Metabolism

Cited by 335

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., et al. (2015) · Haematologica

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 73

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48

Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups

Jagannath, S., Richter, J., Dhodapkar, M. V., Hoffman, J. E., Lee, H. C., Suvannasankha, A., Shah, M. R., Lentzsch, S., Zonder, J. A., Baz, R., et al. (2024) · Cancer Research

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 6